Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Eculizumab, a humanized monoclonal antibody against the terminal complement component 5, was shown to significantly reduce the risk of Neuromyelitis optica spectrum disorder (NMOSD) relapse in a Phase III placebo-controlled trial. Based on this, eculizumab was the first drug to be formally FDA approved for the treatment of anti-AQP4-antibody positive Neuromyelitis optica spectrum disorder (NMOSD) in 2019.
…